Related references
Note: Only part of the references are listed.A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Jeffrey E. Lancet et al.
BLOOD (2007)
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia:: results from Cancer and Leukemia Group B 8461
Sherif S. Farag et al.
BLOOD (2006)
Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon
R Latagliata et al.
ANNALS OF ONCOLOGY (2006)
Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival
G Juliusson et al.
LEUKEMIA (2006)
Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia:: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori et al.
LEUKEMIA (2005)
Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia
CC Chen et al.
ANNALS OF ONCOLOGY (2005)
Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older
C Nabhan et al.
LEUKEMIA RESEARCH (2005)
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
JM Rowe et al.
BLOOD (2004)
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine.: A randomized population-based phase II study
G Juliusson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment:: a single-center retrospective study
B Behringer et al.
ANNALS OF HEMATOLOGY (2003)
Assessment of differences in patient populations selected for or excluded from participation in clinical phase III acute myelogenous leukemia trials
C Mengis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
JE Anderson et al.
BLOOD (2002)
The outcomes and costs of acute myeloid leukemia among the elderly
J Menzin et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Adhesion of human platelets to serum amyloid A
S Urieli-Shoval et al.
BLOOD (2002)
Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
EH Estey et al.
BLOOD (2001)
Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia
A Wahlin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
D Grimwade et al.
BLOOD (2001)
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
AH Goldstone et al.
BLOOD (2001)
Share Paper
